Robert Jenkins

Department of Laboratory Medicine and Pathology
Mayo Clinic

Robert B. Jenkins, MD, PhD, professional career has been focused on cancer genetics, particularly elucidation of the genetic events important for cancer initiation and progression. His cancer genetics efforts have encompassed both basic genetic investigations as well as clinical translation of those basic genetic observations. Dr. Jenkins' primary interest has been centered on the genetics of gliomas, where both his basic genetic studies and clinical translation activities have had a major impact on neuro-oncology. The Jenkins lab has worked in other areas of neuro-oncology. For example, his lab discovered that 1p/19q codeletion is assocaited with tumors of olidogendroglial lineage and predicts response to chemotherapy and radiation therapy. They also developed a FISH test that is used world-wide to test for these deletions. They developed carrier peptides to deliver proteins and small molecules across the blood-brain barrier (BBB). This technology has been licensed by several drug companies and is showing evidence of success for the treatment of neurologic disorders. The lab has developed new diagnostic and predictive tests for use in for various cancers. The Jenkins lab was involved in the development of the FDA-approved dual-probe fluorescence in situ hybridization (FISH) test that is used to stratify patients for the treatment with HER2 targeted therapies. With the company Genome Diagnostics Inc. they developed an expression profiling test that predicts which men with prostate cancer are likely to develop clinical progression. This test is now included in the NCCN prostate cancer diagnostic guidelines. Dr. Jenkins has been involved in the development of several other genetic tests, including multiple FISH and array comparative genomic hybridization (aCGH) tests. In the CIM conference he will be discussing the development of mate-pair NGS for use as a clinical cytogenetics test.

Presentation(s):

Send Email for Robert Jenkins